What if treating disease meant stabilizing biology, not blocking it? We explore that idea in @ScienceMagazine with LOCKTAC molecular glues, a new class of molecules that stabilize natural interactions to either boost or block biology. https://t.co/nfP5GV696s
#mycompnay
Excited to share our discovery of a new programmable RNA-guided DNA-targeting system hiding inside bacteriophages that predates CRISPR.
We call it VIPR (Viral Interference Programmable Repeat), and it uses an entirely new logic to find its targets.
Thread + link below.
What if a small molecule could activate a transcription factor program in one cell type and destroy the same pathway in another? In our new preprint, we describe one such story on bifunctional molecules that toggle between transactivation and repression.
Functional inactivation of the telomerase chaperone TCAB1 primes cells for the activation of ALT in osteosarcoma https://t.co/7WxggjkWin #biorxiv_cancer
Selinexor is an allosteric degrader: it stabilizes XPO1/CRM1 to expose a cryptic ASB8 E3 ligase site, triggering ubiquitination. Led by Casey Wing, Joyce Fung & Bert Kwanten. #TargetedDegradation#Allostery
https://t.co/aCvxF1UbFa
Thrilled to share that I have joined @Amgen
as the inaugural Amgen Science Fellow. I look forward to partnering with colleagues to design next-gen therapeutic by integrating AI/ML with high throughput synthetic biology platforms.
https://t.co/Rbt2ya1rS9
Legend David Baltimore died yesterday. He understood the way things should work: "the real contribution of @MIT is that it doesn't take itself too seriously. It takes ideas seriously, but the people are relatively informal. They are not self-aggrandizing the way academics can be.
Thrilled to share our work to find natural products that inhibit β-catenin! This is the result of an amazing collaboration with @theNCI Natural Products Branch and shows the power of 'up' assays to find new and interesting molecules! https://t.co/OR3BZFzMrx
A new #ScienceReview looks at a different approach to drug discovery that may enable drugging of unconventional targets through stabilization of macromolecular complexes with molecules known as “LOCKTACs.”
Learn more: https://t.co/seRQqjQVYv
Great to see our two in-house developed kinetic stabilizers, Tolcapone and PITB, against transthyretin amyloidoses cited as examples of an emerging therapeutic class: LOCKTACS. https://t.co/a7ZsuNAzMB
Talking of @amgen they also have cool LYMTACs: chimeric small molecules repurpose lysosomal membrane proteins for target protein relocalization & degradation https://t.co/EkliolNtOG
Degradation without E3s?
Cool approach here - molecules that drag membrane proteins into lysosomes for degradation
Might help get around KRASi resistance
What if treating disease meant stabilizing biology, not blocking it? We explore that idea in @ScienceMagazine with LOCKTAC molecular glues, a new class of molecules that stabilize natural interactions to either boost or block biology. https://t.co/nfP5GV696s
#mycompnay
Amgen’s LOCKTAC molecular glues are changing how we target disease.
🔬 AMG 193, now in clinical trials, is designed to lock PRMT5 to MTA in MTAP-deleted tumors.
Read more about how Amgen is working to innovate in this spaceAmgen’s LOCKTAC molecular glues are changing how we target disease.
🔬 AMG 193, now in clinical trials, is designed to lock PRMT5 to MTA in MTAP-deleted tumors.
Read more about how Amgen is working to innovate in this spaceAmgen’s LOCKTAC molecular glues are changing how we target disease.
🔬 AMG 193, now in clinical trials, is designed to lock PRMT5 to MTA in MTAP-deleted tumors.
Read more about how Amgen is working to innovate in this spaceAmgen’s LOCKTAC molecular glues are changing how we target disease.
🔬 AMG 193, now in clinical trials, is designed to lock PRMT5 to MTA in MTAP-deleted tumors.
Read more about how Amgen is working to innovate in this space.
Check out how we repurpose lysosomal membrane proteins for targeted protein relocalization and degradation using LYMTAC molecules. Now published in @NatureComms. Congrats to @nalawansha and team! #mycompany
https://t.co/uCQJYWigsi
🚨New @biorxivpreprint from the @Amgen Induced Proximity group. Here we introduce LYMTACs: Chimeric Small Molecules Repurpose Lysosomal Membrane Proteins for Target Protein Relocalization and Degradation. 🧵 https://t.co/19IFe2Ib8M